SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...

Cytokinetics, Incorporated has a one year low of $39.81 and a one year high of $75.71. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28.

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in ...

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ:CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...

Cytokinetics (NASDAQ:CYTK) added ~10% in the premarket on Wednesday after its rival Edgewise Therapeutics (NASDAQ:EWTX) posted topline data from a mid-stage trial for EDG-7500, an experimental ...

Comparatively, Cytokinetics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Cytokinetics (CYTK) announced the launch of EARTH-HCM, an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic ...

SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin ...

On Thursday, Cantor Fitzgerald reiterated its Overweight rating on shares of Cytokinetics (NASDAQ:CYTK), with a focus on the company’s heart failure treatment, Afi™. While the stock is currently ...